Intra-arterial thrombolytic therapy: a combined approach with angioplasty and/or minor surgery.
Low-dose intra-arterial treatment was performed in 124 patients who underwent a total of 142 procedures. The series included 87 occluded arteries and 55 occluded grafts. In only 29 instances (21%) was thrombolysis alone sufficient. In another 77 procedures (54%) the thrombolysis was followed by either angioplasty or minor surgery. In the remaining 36 treatments (25%) lysis of the occlusion failed. A successful end result of combined treatment was achieved in 67 of 77 (87%) procedures. Including the 29 patients in whom thrombolysis alone sufficed, a total of 96 of the 142 procedures (67%) were successful, with the overall success rate being better in grafts (78%) than in arteries (61%). The suprainguinal lesions had a significantly better response compared to the infra-inguinal ones. The evaluation of all procedures was done at the time of discharge from hospital. Complications were related either to local or systemic hemorrhage or distal embolization. Death related to treatment occurred in three patients.
Morag
B
B
Department of Diagnostic Imaging, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Garniek
A
A
Setton
A
A
Schneiderman
J
J
Walden
R
R
Rubinstein
Z
Z
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000792:Angiography; D000800:Angioplasty, Balloon / Q000009:adverse effects / Q000379:methods*; D001157:Arterial Occlusive Diseases / Q000145:classification / Q000000981:diagnostic imaging / Q000628:therapy*; D002423:Cause of Death; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006083:Graft Occlusion, Vascular / Q000145:classification / Q000000981:diagnostic imaging / Q000628:therapy*; D006801:Humans; D007269:Injections, Intra-Arterial / Q000009:adverse effects / Q000379:methods*; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index; D013300:Streptokinase / Q000627:therapeutic use*; D017131:Thrombectomy / Q000009:adverse effects / Q000379:methods*; D015912:Thrombolytic Therapy / Q000009:adverse effects / Q000379:methods*; D013927:Thrombosis / Q000145:classification / Q000000981:diagnostic imaging / Q000628:therapy*; D017211:Treatment Failure; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*
D013300:Streptokinase; D014568:Urokinase-Type Plasminogen Activator